Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tryptamine Therapeutics ( (AU:ENP) ) has provided an update.
Entropy Neurodynamics Limited has issued 13,823,528 fully paid ordinary shares, informing the market that the placement was conducted without a disclosure document under the relevant provisions of the Corporations Act. The company stated it remains compliant with its financial reporting and continuous disclosure obligations and confirmed there is no excluded information that would affect secondary trading of the newly issued shares.
The announcement, authorised by the board, effectively clears the way for secondary trading of these new shares by satisfying the legal notice requirements under section 708A(5)(e) of the Corporations Act. This step supports liquidity for existing and new shareholders and signals that Entropy Neurodynamics is adhering to regulatory standards while potentially strengthening its capital base through the new equity issuance.
More about Tryptamine Therapeutics
Entropy Neurodynamics Limited, listed on the ASX under the ticker ENP, operates in the neurotechnology and life sciences sector. The company focuses on developing and commercialising innovations related to neurological disorders and brain function, targeting investors interested in early-stage medical and neurodynamics technologies.
Average Trading Volume: 2,377,684
Technical Sentiment Signal: Sell
Current Market Cap: A$48.52M
For detailed information about ENP stock, go to TipRanks’ Stock Analysis page.